This patent teaches ways of inactivating xenogeneic carbohydrate antigens and replacing them with non-immunogenic antigens so that various porcine and animal tissue may be transplanted into humans without the fear of hyperacute rejection.
Since the problem of allogeneic rejection is still an issue, the clinical translation of this technology will most likely be long-term. Specifically, if it is possible to generate the tissue described in the patent, there are numerous other antigens in addition to carbohydrate antigens that would mediate rejection in a xenogeneic host.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.